Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2803MR)

This product GTTS-WQ2803MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2803MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6136MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ3477MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ5993MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ9768MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ9673MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ3975MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ7228MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ15495MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW